Search research articles
Contact Us
Filters
Showing results (81-90 of 106) with videos related to
Page
of 11
Sort By:
Circulation
|
June 25, 2015
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Alvaro Avezum, Renato D Lopes, Phillip J Schulte, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 18, 2016
Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial
Justin A Ezekowitz, Basil S Lewis, Renato D Lopes, et al.
American Heart Journal
|
June 5, 2017
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization
Anthony J Dalby, Shmuel Gottlieb, Derek D Cyr, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
Raffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
European Heart Journal
|
December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
Claes Held, Elaine M Hylek, John H Alexander, et al.
Journal of the American College of Cardiology
|
May 7, 2016
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial
Pascal Vranckx, Harvey D White, Zhen Huang, et al.
European Heart Journal. Acute Cardiovascular Care
|
October 21, 2020
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy
Batric Popovic, Emmanuel Sorbets, Jeremie Abtan, et al.
Circulation
|
May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
, John H Alexander, Richard C Becker, et al.
JAMA
|
April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
Steven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Circulation
|
September 15, 2005
NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study
Mariann Gyöngyösi, Aliasghar Khorsand, Sholeh Zamini, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 106) with videos related to
Sort By:
Page
of 11
Circulation
|
June 25, 2015
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Alvaro Avezum, Renato D Lopes, Phillip J Schulte, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 18, 2016
Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial
Justin A Ezekowitz, Basil S Lewis, Renato D Lopes, et al.
American Heart Journal
|
June 5, 2017
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization
Anthony J Dalby, Shmuel Gottlieb, Derek D Cyr, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
Raffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
European Heart Journal
|
December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
Claes Held, Elaine M Hylek, John H Alexander, et al.
Journal of the American College of Cardiology
|
May 7, 2016
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial
Pascal Vranckx, Harvey D White, Zhen Huang, et al.
European Heart Journal. Acute Cardiovascular Care
|
October 21, 2020
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy
Batric Popovic, Emmanuel Sorbets, Jeremie Abtan, et al.
Circulation
|
May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
, John H Alexander, Richard C Becker, et al.
JAMA
|
April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
Steven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Circulation
|
September 15, 2005
NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study
Mariann Gyöngyösi, Aliasghar Khorsand, Sholeh Zamini, et al.
Page
of 11